Activest Wealth Management’s Cartesian Therapeutics RNAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$476 Hold
66
– – ﹤0.01% 905
2026
Q2
$688 Hold
66
– – ﹤0.01% 1017
2026
Q1
$406 Hold
66
– – ﹤0.01% 1088
2025
Q4
$476 Hold
66
– – ﹤0.01% 1002
2025
Q3
$675 Hold
66
– – ﹤0.01% 931
2025
Q2
$686 Hold
66
– – ﹤0.01% 822
2025
Q1
$870 Hold
66
– – ﹤0.01% 785
2024
Q4
$1.18K Hold
66
– – ﹤0.01% 456
2024
Q3
$1.06K Hold
66
– – ﹤0.01% 457
2024
Q2
$1.78K Buy
+66
New +$1.58K ﹤0.01% 407

Other funds holding RNAC

Activest Wealth Management's RNAC Position: Q3 2026 in Review

Activest Wealth Management held its Cartesian Therapeutics (RNAC) position steady in Q3 2026 at 66 shares worth $476. The position accounts for ﹤0.01% of the portfolio, ranked #905.

Activest Wealth Management first reported a position in RNAC in Q2 2024 and has held it in 10 quarters since. The position peaked at $1.78K in Q2 2024. 100 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Activest Wealth Management held 66 shares of Cartesian Therapeutics worth $476 as of Q3 2026.
  • Activest Wealth Management left its Cartesian Therapeutics share count unchanged in Q3 2026.
  • Cartesian Therapeutics made up ﹤0.01% of Activest Wealth Management's portfolio in Q3 2026, its #905 holding.
  • Activest Wealth Management first reported a position in Cartesian Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • Activest Wealth Management's Cartesian Therapeutics position peaked at $1.78K in Q2 2024.
  • 100 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Activest Wealth Management's 13F filing for Q3 2026, filed 15 Oct 2026.